<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Childhood autologous hematopoietic cell transplant (auto-HCT) survivors can be at risk for secondary malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (SMNs) </plain></SENT>
<SENT sid="1" pm="."><plain>We assembled a cohort of 1487 pediatric auto-HCT recipients to investigate the incidence and risk factors for SMNs </plain></SENT>
<SENT sid="2" pm="."><plain>Primary diagnoses included <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> (39%), <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (26%), <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (18%), central <z:mp ids='MP_0008912'>nervous</z:mp> system <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (14%) and <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> (2%) </plain></SENT>
<SENT sid="3" pm="."><plain>Median follow-up was 8 years (range, &lt;1-21 years) </plain></SENT>
<SENT sid="4" pm="."><plain>SMNs were reported in 35 patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)=13, solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>=20, subtype missing=2) </plain></SENT>
<SENT sid="5" pm="."><plain>The overall cumulative incidence of SMNs at 10 years from auto-HCT was 2.60% (<z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>=1.06%, <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>=1.30%) </plain></SENT>
<SENT sid="6" pm="."><plain>We found no association between SMNs risk and age, gender, diagnosis, disease status, time since diagnosis or use of TBI or <z:chebi fb="0" ids="4911">etoposide</z:chebi> as part of conditioning </plain></SENT>
<SENT sid="7" pm="."><plain>OS at 5-years from diagnosis of SMNs was 33% (95% confidence interval (CI), 16-52%) </plain></SENT>
<SENT sid="8" pm="."><plain>When compared with age- and gender-matched general population, auto-HCT recipients had 24 times higher risks of developing SMNs (95% CI, 16.0-33.0) </plain></SENT>
<SENT sid="9" pm="."><plain>Notable SMN sites included bone (N=5 SMNs, observed (O)/expected (E)=81), thyroid (N=5, O/E=53), breast (N=2, O/E=93), soft tissue (N=2, O/E=34), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (N=6, O/E=266) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (N=7, O/E=6603) </plain></SENT>
<SENT sid="10" pm="."><plain>Risks of SMNs increased with longer follow-up from auto-HCT </plain></SENT>
<SENT sid="11" pm="."><plain>Pediatric auto-HCT recipients are at considerably increased risk for SMNs and need life-long surveillance for SMNs </plain></SENT>
</text></document>